Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo

被引:108
作者
Arbiser, JL
Larsson, H
Claesson-Welsh, L
Bai, XH
LaMontagne, K
Weiss, SW
Soker, S
Flynn, E
Brown, LF
机构
[1] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA
[3] Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA USA
[4] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA
[5] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden
关键词
D O I
10.1016/S0002-9440(10)65015-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular endothelial growth factor (VEGF or vascular permeability factor) is an important angiogenic factor that is up-regulated in numerous benign and malignant disorders, including angiosarcoma, hemangiomas, and solid tumors. To determine the functional role of VEGF in the development of endothelial tumors, we expressed primate VEGF 121 in an endothelial cell line, MS1, derived from primary murine cells by immortalization with a temperature-sensitive SV40 large T antigen. This cell line expresses the VEGFR-2 (Flk-1/Kdr) receptor for VEGF. Expression of VEGF 121 led to the development of slowly growing endothelial tumors, which were histologically well-differentiated angiosarcomas. The angiosarcomas generated from MS1 VEGF cells demonstrated up-regulation of the VEGF receptors VEGFR-2 and VEGFR-1 (Flt-1) in vivo compared with benign hemangiomas generated from MS1 cells. Treatment of these cells with the VEGFR-2 tyrosine kinase inhibitor SU 1498 led to decreased expression of ets-1, a transcription factor which has been shown to be stimulated by VEGF. These results suggest that high level expression of VEGF in endothelial cells may result in malignant transformation. This transformation process likely involves both autocrine and paracrine pathways.
引用
收藏
页码:1469 / 1476
页数:8
相关论文
共 47 条
[31]  
RAK J, 1995, CANCER RES, V55, P4575
[32]  
SCHMITZRIXEN T, 1984, LYMPHOLOGY, V17, P50
[33]   TUMOR-CELLS SECRETE A VASCULAR-PERMEABILITY FACTOR THAT PROMOTES ACCUMULATION OF ASCITES-FLUID [J].
SENGER, DR ;
GALLI, SJ ;
DVORAK, AM ;
PERRUZZI, CA ;
HARVEY, VS ;
DVORAK, HF .
SCIENCE, 1983, 219 (4587) :983-985
[34]   FAILURE OF BLOOD-ISLAND FORMATION AND VASCULOGENESIS IN FLK-1-DEFICIENT MICE [J].
SHALABY, F ;
ROSSANT, J ;
YAMAGUCHI, TP ;
GERTSENSTEIN, M ;
WU, XF ;
BREITMAN, ML ;
SCHUH, AC .
NATURE, 1995, 376 (6535) :62-66
[35]  
Shibuya M, 1999, CURR TOP MICROBIOL, V237, P59
[36]   INDUCTION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR EXPRESSION BY HYPOXIA AND BY GLUCOSE DEFICIENCY IN MULTICELL SPHEROIDS - IMPLICATIONS FOR TUMOR ANGIOGENESIS [J].
SHWEIKI, D ;
NEEMAN, M ;
ITIN, A ;
KESHET, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (03) :768-772
[37]   P53 MUTATIONS IN PRIMARY HEPATIC ANGIOSARCOMAS NOT ASSOCIATED WITH VINYL-CHLORIDE EXPOSURE [J].
SOINI, Y ;
WELSH, JA ;
ISHAK, KG ;
BENNETT, WP .
CARCINOGENESIS, 1995, 16 (11) :2879-2881
[38]   Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor [J].
Soker, S ;
Takashima, S ;
Miao, HQ ;
Neufeld, G ;
Klagsbrun, M .
CELL, 1998, 92 (06) :735-745
[39]  
STEWART NJ, 1995, CLIN ORTHOP RELAT R, P135
[40]   Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases [J].
Sun, L ;
Tran, N ;
Tang, F ;
App, H ;
Hirth, P ;
McMahon, G ;
Tang, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (14) :2588-2603